On April 24, NeuroMax, Ltd., a portfolio company of Maxwell Biotech Venture Fund, founded with the participation of RVC, received an authorization by the Ministry of Healthcare and Social Development of the Russian Federation to carry out clinical trials of its drug candidate NM-IA-001 (choline diepalrestat, BNV-222). With this authorization, NeuroMax can start studying the safety and pharmacokinetics of the drug in patients with diabetic polyneuropathy. The study will be carried out in the E.A. Vagner Perm State Medical Academy.
Nowadays, there are no drugs for pathogenetic treatment of diabetes complications, such as NM-IA-001 (BNV-222). The new drug candidate is a low-molecular inhibitor of aldose reductase ferment. This drug slows down diabetic neuropathy, which is the main indication for its administration. The drug can be also used to treat other diabetic complications, including diabetic nephropathy and retinopathy.
Last autumn the company successfully completed a series of preclinical trials of the efficiency and safety of NM-IA-001 (BNV-222), which showed high efficiency and considerable slowing down of the diabetic polyneuropathy. Due to this success, the company can proceed with the stage of the clinical trials of this drug. If all phases of the clinical trials show positive results, NM-IA-001 (BNV-222) may become the first drug in Russia for pathogenetic treatment of diabetic neuropathy.
Nikolay Golub, CEO of NeuroMax, “The studies are scheduled to start in early summer. We confidently expect positive results from the first phase of the study, and then we will start the second phase in the autumn. We do everything possible so that the new highly efficient drug could become available to Russian patients, suffering from diabetic neuropathy, as soon as possible.”